Stock Price
2.33
Daily Change
-0.04 -1.69%
Monthly
-20.48%
Yearly
76.52%
Q2 Forecast
2.28

Galectin Therapeutics reported $-7.42M in EBITDA for its fiscal quarter ending in December of 2021.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Galectin Therapeutics USD -7.42M 819K Dec/2021
Gilead Sciences USD 3.02B 1.01B Dec/2025
Immunic USD -22.78M 753K Jun/2024
Incyte USD 414.5M 92.42M Dec/2025
Merck USD 8.39B 1.97B Sep/2025